

# Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors

Takayoshi Suzuki\* and Naoki Miyata\*


Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan

**Abstract:** While most inhibitors of histone deacetylases (HDACs) are hydroxamic acid derivatives, several non-hydroxamates have recently been developed as inhibitors and attracted quite a deal of attention. In this review, we present the rational design, inhibitory effect and antiproliferative activity of non-hydroxamate HDAC inhibitors.

**Keywords:** Histone deacetylase, inhibitor, hydroxamic acid, non-hydroxamate, zinc enzyme, rational drug design, anticancer agent.

## INTRODUCTION

In eukaryotes, genetic information is packed in a higher order structure called the chromatin. The fundamental building blocks of chromatin are nucleosomes where genomic DNA is wrapped tightly around core histones [1, 2]. Post-transcriptional modifications of the histones are associated with alterations of chromatin structure that can effect gene expression [3]. The notion that gene expression is regulated by modifications to histones, the so called "histone-code hypothesis" [4, 5], is based on the assumption that these modifications create a specific pattern of substitutions. Acetylation is by far the most studied specific histone modification. The acetylation of specific histone lysine residues is catalyzed by histone acetyltransferases (HATs). Histone acetylation is a reversible process that is regulated by the opposing activities of HATs and histone deacetylases (HDACs) (Fig. 1). In general, hyperacetylation of histone lysine residues correlates with transcriptional activation whereas deacetylation relates to transcriptional silencing [6-9].



**Fig. (1).** Reversible acetylation of specific histone lysine residues.

\*Address correspondence to these authors at the Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan; Tel/Fax: +81-52-836-3407; E-mail: suzuki@phar.nagoya-cu.ac.jp; miyata-n@phar.nagoya-cu.ac.jp

The inhibition of HDACs causes histone hyperacetylation and leads to the transcriptional activation of genes such as *p21<sup>WAF1/CIP1</sup>* [10], *FAS* and *caspase-3* [11] which are associated with cell cycle progression, differentiation or tumorigenesis. Therefore, HDAC inhibitors have emerged as a new generation of anticancer agents. Indeed, HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA) [12] (Fig. 2) are currently in phase III clinical trials for the treatment of cancer. To date, a number of structurally diverse HDAC inhibitors have been reported [13-18]. To the best of our knowledge, previously reported HDAC inhibitors predominantly rely on hydroxamic acid structures like SAHA, Trichostatin A (TSA) [19, 20] and 3-(4-aryl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides such as **1** and **2** [21] (Fig. 2) to achieve the desired effect. However, hydroxamic acids are often poorly absorbed *in vivo* and carry potential metabolic liabilities such as glucuronidation and sulfation [22, 23]. Furthermore, many hydroxamates are prone to hydrolysis *in vivo* giving hydroxylamine which has potential mutagenic properties [24]. Thus, there has been considerable interest in developing non-hydroxamate HDAC inhibitors. Until very recently, known non-hydroxamate HDAC inhibitors were small fatty acids such as sodium butyrate and valproic acid, and *o*-aminoanilides such as MS-275 (Fig. 3) [25-34]. However, most of these are less potent than hydroxamates. Therefore, we and others have searched for replacements for hydroxamic acid with the goal of producing new drugs as well as finding new tools for biological research, and have identified several non-hydroxamate HDAC inhibitors [35-44]. In this review, the rational design and biological activity of non-hydroxamate HDAC inhibitors are presented.

## THREE-DIMENSIONAL STRUCTURE AND CATALYTIC MECHANISM OF HDAC

In 1999, Finin and co-workers published the X-ray crystal structure of an archaeobacterial HDAC homologue (HDAC-like protein, HDLP)/SAHA or TSA [45]. It was revealed that the enzyme contains a zinc ion at the bottom of its active site and that the hydroxamic acid group coordinates the zinc ion through its CO and OH groups and also forms three hydrogen bonds between its CO, NH and OH groups and Tyr 297, His 132 and His 131, respectively (Fig. 4). The disclosure has led to a solid understanding of not only the three-dimensional structure of the active site of HDACs but




Fig. (2). Hydroxamate HDAC inhibitors.

also the catalytic mechanism for the deacetylation of acetylated lysine substrates. The proposed mechanism is depicted in Fig. 5. The carbonyl oxygen of the substrate could bind the zinc, and the carbonyl could be located adjacent to the water molecule that chelates the zinc ion. The

(5) [35, 38], which could coordinate the zinc ion bidentately and could also form hydrogen bonds with tyrosine and two histidines like hydroxamic acid (Fig. 7b). We also designed monodentate ZBGs. Thiol 6, thioacetate 7 and methylsulfide 8 were designed based on the high thiophilicity of zinc ion




Fig. (3). Structures of sodium butyrate, valproic acid and MS-275.

carbonyl carbon, which becomes a better electrophile through its chelation with the zinc ion, could be attacked by the water molecule activated by His 140 (HDAC1 numbering) and the zinc ion. The nucleophilic attack would result in a tetrahedral carbon-containing transition state, which could be stabilized by two zinc-oxygen interactions and by a hydrogen bond from the Tyr 303 hydroxyl group. In the final step, a proton transfer from His 141 to the nitrogen of the intermediate would trigger the scission of the carbon-nitrogen bond and yield the acetate and lysine products. The crystal structures of human HDAC8 complexed with hydroxamic acid inhibitors, reported recently [46, 47], also supported such a catalytic mechanism of HDACs.

## MOLECULAR DESIGN OF NON-HYDROXAMATE HDAC INHIBITORS

### Structure-Based Drug Design

On the basis of the three-dimensional structure of the active site of the enzyme, SAHA-based non-hydroxamates were designed and synthesized as HDAC inhibitors (Fig. 6). As mentioned above, the co-crystal structure of HDLP/hydroxamate or HDAC8/hydroxamate made it clear that the hydroxamic acid group chelates the zinc ion in a bidentate fashion and forms hydrogen bonds with tyrosine and two histidines [45-47] (Fig. 7a). As bidentate zinc-binding groups (ZBGs), we designed SAHA-based hydroxyurea (3), semicarbazide (4) and hydroxysulfonamide

[36, 38]. In particular, thiol could interact not only with zinc ion but with amino acid residues in the active site. Another newly designed monodentate ZBG is sulfoxide (9) [39]. Since sulfoxide has a partial negative charge on its oxygen, it is estimated to chelate zinc ion and inhibit HDACs. Irreversible HDAC inhibitors were also designed based on the three-




Fig. (4). SAHA in the catalytic core of HDLP.




Fig. (5). Proposed catalytic mechanism for the deacetylation of acetylated lysine.




Fig. (6). SAHA-based non-hydroxamate compounds designed based on the three-dimensional structure of HDAC.

dimensional structure of the active site of HDLP or HDAC8. As described above, the crystal structures of the HDLP/hydroxamate and HDAC8/hydroxamate complexes revealed that the active site of HDACs is constructed mainly from nucleophilic amino acids such as histidine and aspartic acid [45-47]. Since the imidazole group of histidine and the carboxylate anion of aspartic acid are able to react with electrophiles, we designed analogues bearing propargyl amino (**10**, **11**) and bromoacetamide (**12**) which could form covalent bonds with histidines or aspartic acids of the enzyme [35, 38]. Schultz and co-workers also designed *N*-

formyl hydroxylamine **13** on the basis of the co-crystal structure of HDLP/SAHA or HDLP/TSA [40]. Compounds bearing *N*-formyl hydroxylamine could inhibit HDACs by forming a bidentate chelate with the zinc ion in the active site of HDACs.

Mai and co-workers designed several non-hydroxamates based on the structure of **1** or **2**, hydroxamate HDAC inhibitors identified by them (Fig. **8**) [21]. Some hydroxamic acid-like derivatives **14**–**22** bearing *O*-methylhydroxamate (**14**), hydrazine (**15**), 2-hydroxyethylamide (**16**), *o*-hydroxyanilide (**17**), monophosphonic acid (**18**), nitrile (**19**), barbiturate (**20**), thiobarbiturate (**21**) and amidine (**22**) moieties are able to chelate the zinc ion and are expected to inhibit HDACs.

### Mechanism-Based Drug Design

We and other groups designed SAHA-based non-hydroxamates based on the proposed catalytic mechanism for the deacetylation of acetylated lysine residues (Fig. **9**). We initially designed substrate analogues based on the proposed deacetylation mechanism whereby a zinc-chelating water molecule activated by histidine makes a nucleophilic attack on the carbonyl carbon of an acetylated lysine substrate (Fig. **10a**) [45-47]. With this mechanism, the HDACs would supposedly be inhibited if the water molecule is forcibly removed from the zinc ion, and then heteroatom-containing substrate analogues **23**–**26** were designed [37, 38]. These analogues would be recognized as substrates by HDACs and be easily taken into the active site where they would force the water molecule off the zinc ion and the reactive site for deacetylation through chelation of the heteroatom to the zinc ion, and behave as HDAC inhibitors (Fig. **10b**).

The other design was based on the transition state (TS) structure of HDAC deacetylation, which was estimated to include a tetrahedral carbon [45-47] (Fig. **11a**) as with other zinc proteases [48]. TS analogue inhibitors were designed




Fig. (7). Model for the binding of SAHA (a) and hydroxamic acid mimics 3–5 in the catalytic core of HDAC1.

independently by us [37, 38] and Etkorn *et al* [49]. Phosphone- and sulfone-based SAHA analogues could be TS analogue inhibitors because they have sufficient similarity with the TS of amide bond hydrolysis (Fig. 11b and 11c), both from a steric and an electronic point of view [50]. Then, compounds 27–31, in which a hydroxamic acid of SAHA is replaced by sulfonamide, sulfone, phosphoramidate, phosphonate and phosphinate, respectively, were designed as TS analogues. Frey and co-workers at Abbott designed electrophilic ketones such as 32 and 33 [41-44]. The hydrated form of electrophilic ketones could act as a TS analogue and coordinate the zinc ion in the active site of HDACs [51] (Fig. 11d).

### ENZYME INHIBITORY ACTIVITY

Compounds 3–33 were tested with an *in vitro* enzyme assay. Compound 34 [32], where the hydroxamic acid of SAHA is replaced with *o*-aminoanilide, was prepared and tested as a reference compound. The results are summarized in Tables 1-3.

Table 1 shows the inhibitory activity toward human HDACs of SAHA-based non-hydroxamates 3-13 designed based on the three-dimensional structure of HDAC. The IC<sub>50</sub> values of SAHA and *o*-aminoanilide 34 were 0.28 μM and 120 μM, respectively. Among newly synthesized compounds 3–5, which were designed as compounds with bidentate








Fig. (8). Non-hydroxamates designed based on the structure of 1 or 2.




- 23: R = -NHCOCH<sub>2</sub>NH<sub>2</sub>, n = 5  
 24: R = -NHCOCH<sub>2</sub>OH, n = 5  
 25: R = -NHCOCH<sub>2</sub>SH, n = 5  
 26: R = -NHCOCH<sub>2</sub>SAc, n = 5  
 27: R = -NHSO<sub>2</sub>Me, n = 5  
 28: R = -SO<sub>2</sub>Me, n = 6




**Fig. (9).** SAHA-based non-hydroxamates designed based on the catalytic mechanism for the deacetylation of acetylated lysine substrates.

ZBGs, hydroxyurea **3** and semicarbazide **4** showed inhibitory activity although they were much less effective than SAHA [35, 38]. As to the compounds with monodentate ZBGs (**6–9**), the activity of thiol **6** was far greater than

expected. Although the inhibitory ability of monodentate ZBGs was thought to be less than that of bidentate ZBGs such as hydroxamic acid, a pronounced inhibitory effect




**Fig. (10).** Mechanism proposed for the deacetylation of acetylated lysine substrate (a), and model for the binding of hetero atom-containing substrate analogues to zinc ion (b).



**Fig. (11).** Transition state proposed for HDACs (a), and models for the binding of sulfone derivatives (b), phosphone derivatives (c) and hydrated electrophilic ketones (d).

**Table 1.** HDAC Inhibition Data for SAHA and SAHA-Based Non-Hydroxamates 3–13 and 34 [35, 38, 40]



Compd.	R	n	IC <sub>50</sub> (μM) <sup>a</sup>
SAHA	-CONHOH	6	0.28
34		6	120
3	-NHCONHOH	5	80
4	-NHCONHNH <sub>2</sub>	5	150
5	-SO <sub>2</sub> NHOH	6	> 100
6	-SH	6	0.21
7	-SAc	6	7.1
8	-SMe	6	> 100
9	-S(O)Me	6	48
10		6	> 100
11		6	> 100
12	-NHCOCH <sub>2</sub> Br	6	14
13		6	4.0 <sup>b</sup>
			11 <sup>c</sup>


<sup>a</sup>Activity against a mixture of HDACs in HeLa nuclear extracts. <sup>b</sup>Activity against HDAC2. <sup>c</sup>Activity against HDAC8.

(IC<sub>50</sub> = 0.21 μM) was observed with thiol **6** [36, 38], which was much more active than *o*-aminoanilide **34** and as potent as SAHA. The transformation of thiol into thioacetate (**7**) and methylsulfide (**8**) led to an inhibitor that was about 30-fold less potent and a compound devoid of anti-HDAC activity, respectively. These results suggest that the thiolate anion generated under physiological conditions is intimately involved in the interaction with the zinc ion in the active site. In addition, sulfoxide **9**, the other compound with a monodentate ZBG, inhibited HDACs with an IC<sub>50</sub> of 48 μM [39]. Of the three compounds designed as irreversible HDAC inhibitors (**10–12**), bromoacetamide **12** exhibited an IC<sub>50</sub> of 14 μM and its activity was about 9-fold as strong as that of *o*-aminoanilide **34**, but much weaker than that of SAHA [35, 38]. *N*-Formyl hydroxylamine **13** was reported by Schultz *et al* to inhibit HDAC2 and HDAC8 with IC<sub>50</sub>s of 11 μM and 4.0 μM, respectively [40].

Another series of non-hydroxamates **14–22** were evaluated for their inhibitory activity against maize histone deacetylase HD2 (Table 2). Among these compounds, nitrile **19** and amidine **22** displayed anti-HDAC activity with IC<sub>50</sub>s of 27 μM and 23 μM, respectively, although they were 6- to 7-fold less potent than their reference compound **1** [21].

Table 3 shows the inhibitory activity toward human HDACs of SAHA-based non-hydroxamates **23–33** designed based on the catalytic mechanism for the deacetylation of acetylated lysine substrate. We initially investigated the inhibitory activity of hetero atom-containing substrate analogues **23–26**. Potent inhibition was observed with mercaptoacetamide **25**, while aminoacetamide **23** and hydroxyacetamide **24** did not possess inhibitory activity [37, 38]. Mercaptoacetamide **25** exhibited an IC<sub>50</sub> of 0.39 μM, and its activity greatly surpassed that of *o*-aminoanilide **34** and was comparable to that of SAHA. As expected, the

Table 2. HDAC Inhibition Data for 1, 2 and 14–22 [21]




Compd.	R	n	IC <sub>50</sub> (μM) <sup>a</sup>
1		0	3.8
2		1	0.1
14		1	NI <sup>b</sup>
15		1	> 30 <sup>c</sup>
16		0	> 30 <sup>d</sup>
17		1	NI
18		1	NI
19		0	27
20		1	100
21		1	85
22		0	23

<sup>a</sup>Activity against maize HD2. <sup>b</sup>NI = no inhibition at 30 μM. <sup>c</sup>0.2% inhibition at 33.8 μM. <sup>d</sup>0.9% inhibition at 30.5 μM.

transformation of thiol into thioacetate (**26**) led to a much less potent inhibitor. These results suggest that the ease of ionization of thiol is an important factor in the inhibition of HDACs like the case of thiol **6**. Among TS analogues, electrophilic ketones **32** and **33** showed significant inhibitory activity (IC<sub>50</sub> of **32** = 6.7 μM, IC<sub>50</sub> of **33** = 0.34 μM),

whereas sulfone derivatives **27** and **28**, and phosphorus analogues **29**, **30** and **31** were found to be less potent inhibitors [37, 38, 41–44, 49].

Table 3. HDAC Inhibition Data for SAHA and SAHA-Based Non-Hydroxamates 23–34 [37, 38, 41, 42, 49]




Compd.	R	n	IC <sub>50</sub> (μM) <sup>a</sup>
SAHA	–CONHOH	6	0.28
34		6	120
23	–NHCOCH <sub>2</sub> NH <sub>2</sub>	5	> 100
24	–NHCOCH <sub>2</sub> OH	5	> 100
25	–NHCOCH <sub>2</sub> SH	5	0.39
26	–NHCOCH <sub>2</sub> Sac	5	22
27	–NHSO <sub>2</sub> Me	5	7500
28	–SO <sub>2</sub> Me	6	230
29		5	570
30		5	6100
31		5	6100
32	–COCF <sub>3</sub>	6	6.7 <sup>b</sup>
33	–COCONHMe	6	0.34 <sup>b</sup>

<sup>a</sup>Activity against a mixture of HDACs in HeLa nuclear extracts. <sup>b</sup>Activity against a mixture of HDAC1 and HDAC2.


We also studied the mechanism by which thiol **6** and mercaptoacetamide **25** inhibit HDACs in greater detail [37, 38]. Although the sulfhydryl group of **6** and the mercaptoacetamide group of **25** were designed to chelate zinc ion, it is possible that they inhibit HDACs by forming a covalent disulfide bond with cysteine residues on these enzymes. We examined this possibility using a Lineweaver-Burk plot. First, a kinetic enzyme assay was carried out using compound **6** (Fig. 12). The data from this experiment revealed that thiol **6** engages in competitive inhibition with acetylated lysine substrates, with an inhibition constant (*K<sub>i</sub>*) of 0.11 μM. Since cysteine is not a component of the active site of HDACs, the sulfhydryl group of **6** likely interacts with the zinc in the active site. Since thiol **6** proved to be a competitive inhibitor and to act within the active center of HDACs, its mode of binding within this site was studied. The low energy conformation of **6** was calculated when

docked in the model structure based on the X-ray crystal data of HDAC8 using MacroModel 8.1 software. An inspection of




**Fig. (12).** Reciprocal rate vs reciprocal acetylated lysine substrate concentration in the presence of 0.3 (●), 0.1 (▲), 0.03 (■), and 0 (○)  $\mu\text{M}$  of **6**.

the HDAC8/**6** complex shows that the sulfur atom of **6** was located 2.35 Å from the zinc ion, 2.24 Å from the OH group of Tyr 306, and 2.66 Å from a water molecule which forms a hydrogen bond with the imidazole group of His142 (Fig. 13). These results suggest that thiol **6** strongly inhibits HDACs by interacting directly with zinc ion, Tyr 306, and His 142 via a water molecule.




**Fig. (13).** Low energy conformation of **6** docked in the HDAC8 catalytic core.

Next, a Lineweaver-Burk plot was drawn for mercaptoacetamide **25** (Fig. 14). Compound **25** turned out to be an inhibitor competitive with acetylated lysine substrates ( $K_i = 0.78 \mu\text{M}$ ). The low energy conformation of **25** docked in the catalytic core of HDAC8 was also calculated. It was found that the sulfur atom and oxygen atom of **25** were located 2.44 Å and 2.04 Å from the zinc ion, respectively, and that a water molecule, which is required for the deacetylation of acetylated lysine substrates, was positioned 4.95 Å apart from the zinc ion (Fig. 15). This calculation suggests that **25** inhibits HDACs by chelating the zinc ion in a bidentate fashion through its sulfur and oxygen atoms, and by removing a water molecule from the zinc and the reactive site for the deacetylation, without being hydrolyzed by HDACs.




**Fig. (14).** Reciprocal rate vs reciprocal acetylated lysine substrate concentration in the presence of 1 (●), 0.3 (▲), 0.1 (■), and 0 (○)  $\mu\text{M}$  of **25**.

Based on the results shown in Tables 1-3, we selected thiol **6** and further studied its structure-activity relationship in an *in vitro* assay using a HeLa nuclear extract rich in HDAC activity, because it showed the strongest activity of all non-hydroxamates [37, 38]. First, the effect of the linker parts of thiol **6** was examined. The results are shown in Table 4. The inhibition of HDACs was distinctly dependent on chain length, with  $n = 7$  (**35**) and  $n = 4$  (**37**) resulting in less potent inhibitors. However, compound **36**, in which  $n = 5$ , proved to be equally effective as **6**, in which  $n = 6$ . As for the group attaching to the phenyl moiety, ether **38** displayed moderate activity, whereas the activity of the reversed amide **39** was sustained. Next, the aromatic cap part was examined (Table 5). Considering that the entrance of the *N*-acetylated lysine binding channel is composed mainly of aromatic amino acids such as tyrosine and phenylalanine [45-47], we replaced the phenyl group of **6** or **39** with various aromatic



**Fig. (15).** Low energy conformation of **25** docked in the HDAC8 catalytic core.


**Table 4.** Effect of Linker Variation on Inhibitory Activity of Thiols [35, 38]










Compd.	X	n	IC <sub>50</sub> (μM)
6	-NHCO-	6	0.21
35	-NHCO-	7	1.5
36	-NHCO-	5	0.37
37	-NHCO-	4	6.2
38	-O-	6	11
39	-CONH-	6	0.36

groups, which were expected to have higher affinity for HDACs through  $\pi$ - $\pi$  interaction or hydrophobic interaction. In the amide-linked series, 4-substituted phenyl compounds tended to be less active. Specifically, compounds **40** (Ar = 4-NMe<sub>2</sub>-Ph), **41** (Ar = 4-biphenyl) and **43** (Ar = 4-PhO-Ph) were about 3- to 6-fold less potent inhibitors than the parent thiol **6**. On the other hand, 3-biphenyl **42** showed a 3-fold increase in inhibitory activity (IC<sub>50</sub> of 0.075 μM). In addition, 3-phenoxy compound **44** was as active as compound **6**. We also investigated the effect of heteroaryl rings. Changing the phenyl group to a 3-pyridine ring (**45**), 4-phenyl-2-thiazole ring (**47**), and 2-benzothiazole ring (**48**) maintained or slightly reduced the activity, whereas 3-quinoline **46** had improved activity (IC<sub>50</sub> of 0.072 μM). The reverse amide-linked series were at least as active as the parent thiol **39**, with the exception of **49** (Ar = 4-NMe<sub>2</sub>-Ph), which was a slightly less potent inhibitor. In particular, the reversed amides **50** with 2-naphthalene and **51** with 2-benzofuran exhibited about a 3-fold increase in potency (IC<sub>50</sub>s of 0.085 μM and 0.079 μM, respectively). As a result, IC<sub>50</sub>s in the double-digit nanomolar range were observed with 3-biphenyl **42**, 3-quinoline **46**, 2-naphthalene **50**, and 2-benzofuran **51**, which were approximately 3- to 4-fold more potent than SAHA.

### ANTIPROLIFERATIVE ACTIVITY


To confirm the effectiveness of thiol-based HDAC inhibitors as anticancer drugs and tools for biological research, the antiproliferative activity of thiol **6** was examined using human lung cancer NCI-H460 cells [38]. However, compound **6** was found to be only weakly active (Table 6), although **6** was highly active in an enzyme assay. The reason for the weak activity of thiol **6** is unclear, but it is likely due to poor membrane permeability resulting from the highly polar character of this compound. To improve its permeability and its ability to inhibit cancer cell growth, a transient masking of the sulfhydryl group, a prodrug approach, was investigated. As a prodrug of thiol **6**, we prepared disulfide **53**, which was expected to be reduced to release the free thiol **6** in the cellular environment. However, disulfide **53** failed to exhibit a growth inhibitory effect on NCI-H460 cells. Next, we prepared compound **7**, an acetyl derivative of thiol **6**. Compound **7** proved to be relatively

**Table 5.** Effect of Aromatic Group on Inhibitory Activity of Thiols [35, 38]

Compd.	Ar	X	IC <sub>50</sub> (μM)
6	-Ph	-NHCO-	0.21
40		-NHCO-	1.2
41		-NHCO-	1.1
42		-NHCO-	0.075
43		-NHCO-	0.62
44		-NHCO-	0.21
45		-NHCO-	0.11
46		-NHCO-	0.072
47		-NHCO-	0.17
48		-NHCO-	0.34
39	-Ph	-CONH-	0.36
49		-CONH-	0.61
50		-CONH-	0.085
51		-CONH-	0.079
52		-CONH-	0.1

potent compared with thiol **6** and disulfide **53** ( $EC_{50}$  of 36  $\mu\text{M}$ ). On the basis of this finding, we prepared other *S*-acyl compounds (**54–61**) and evaluated their antiproliferative activities. Since the ClogP values of compounds **54–61** are 3.71, 4.24, 4.06, 4.41, 3.54, 4.67, 4.65, respectively, and are larger than that of thiol **6** (ClogP of **6** = 3.17), these compounds were expected to permeate cell membrane more efficiently and show higher cellular activity than **6**. This series of compounds exhibited greater potency than thiol **6** and acetyl compound **7**, except for pivaloyl compound **57**, which was a less potent cell growth inhibitor than **7**. Among them, isobutyryl compound **56** showed about a 2-fold increase in activity when compared to acetyl compound **7** ( $EC_{50}$  of 20  $\mu\text{M}$ ). Since *S*-acyl compounds are weakly active in enzyme assays (e.g.  $IC_{50}$  of **56** > 50  $\mu\text{M}$ ), they could possibly permeate the cell membrane more efficiently than thiol **6**, and be converted to thiol **6** by enzymatic hydrolysis within the cell [52]. The compound bearing a (pivaloyloxy)methyl group [53] (**62**) was slightly less active than isobutyryl compound **56**. With the results shown in Table 6, a selected set of active compounds from the

**Table 6. Antiproliferative Effect on NCI-H460 Cells of Compound 6 and its S-Modified Prodrugs [38]<sup>a</sup>**




Compd.	R	$EC_{50}$ ( $\mu\text{M}$ )
<b>6</b>	–H	>50 <sup>b</sup>
<b>53</b>		>50 <sup>c</sup>
<b>7</b>	–Ac	36
<b>54</b>	–COEt	28
<b>55</b>	–CO <i>n</i> -Pr	22
<b>56</b>	–CO <i>i</i> -Pr	20
<b>57</b>	–CO <i>t</i> -Bu	77
<b>58</b>		27
<b>59</b>		21
<b>60</b>	–Bz	25
<b>61</b>		24
<b>62</b>	–CH <sub>2</sub> OCO <i>t</i> -Bu	25

<sup>a</sup> $EC_{50}$  of SAHA = 1.1  $\mu\text{M}$ . <sup>b</sup>34% inhibition at 50  $\mu\text{M}$ . <sup>c</sup>10% inhibition at 50  $\mu\text{M}$ .

enzymatic assay were *S*-isobutyrylated and evaluated for their antiproliferative activities (Table 7). Changing the phenyl group of compound **56** to other aromatic groups led

to positive results. Isobutyryl analogues **63–71** were generally more potent than the parent compound **56**; the sole exception was **64** (Ar = 3-OPh-Ph) which was a less potent compound. Above all, 3-biphenyl (**63**), 3-pyridinyl (**65**) and 4-phenyl-2-thiazolyl (**67**) analogues showed strong activity in inhibiting the growth of NCI-H460 cells, with  $EC_{50}$ s of 2–3  $\mu\text{M}$ . Furthermore, we evaluated antiproliferative activities of SAHA and 4-phenyl-2-thiazole **67**, the most potent compound in this study, against nine other human cancer cell lines (Table 8). Compound **67** strongly inhibited the growth of various human cancer cells, with  $EC_{50}$  values ranging from 1 to 10  $\mu\text{M}$ , and these antiproliferative activities were comparable to those of SAHA (average  $EC_{50}$  of **67** 3.8  $\mu\text{M}$ , SAHA 3.7  $\mu\text{M}$ ) which is currently being evaluated in phase III clinical trials for use in the treatment of cancer.

**Table 7. Cell Growth Inhibition Data on NCI-H460 Cells for Compound 56 and its Derivatives [38]**




Compd.	Ar	X	$EC_{50}$ ( $\mu\text{M}$ )
<b>56</b>	–Ph	–NHCO–	20
<b>63</b>		–NHCO–	2.8
<b>64</b>		–NHCO–	25
<b>65</b>		–NHCO–	2.9
<b>66</b>		–NHCO–	8.0
<b>67</b>		–NHCO–	2.1
<b>68</b>		–NHCO–	9.5
<b>69</b>		–CONH–	12
<b>70</b>		–CONH–	4.1
<b>71</b>		–CONH–	12

**Table 8. Growth Inhibition of Various Cancer Cells Using SAHA and Compound 67 [38]**

Cell		SAHA	67
		EC <sub>50</sub> (μM)	EC <sub>50</sub> (μM)
MDA-MB-231	Breast Cancer	1.5	2.3
SNB-78	Central Nervous	16	9.1
	System		
HCT116	Colon Cancer	0.58	3.0
NCI-H226	Lung Cancer	2.6	2.6
LOX-IMVI	Melanoma	1.3	1.1
SK-OV-3	Ovarian Cancer	2.5	4.5
RXF-631L	Renal Cancer	2.0	2.4
St-4	Stomach Cancer	5.2	5.0
DU-145	Prostate Cancer	1.6	4.5
Mean		3.7	3.8

By Western blot analysis, compound **67** was shown to give rise to elevated and dose-dependent levels of acetylated histone H4 and p21<sup>WAF1/CIP1</sup> in HCT 116 cells (Fig. 16). These results suggested that the antiproliferative activity of compound **67** significantly correlates with the inhibition of intracellular HDACs.



**Fig. (16).** Western blot analysis of histone hyperacetylation and p21<sup>WAF1/CIP1</sup> induction in HCT 116 cells produced by compound **67** and by reference compound SAHA. HCT116 cells were incubated with compound **67** for 8 h at 37°C.

## PERSPECTIVE

By rational drug design, several new non-hydroxamate structures containing thiols were identified. The discovery of non-hydroxamate inhibitors of HDACs introduced in this review should provide the basis for the development of ideal inhibitors free of the problems associated with hydroxamates.

To date, eleven HDAC isozymes have been identified. Isozyme-selective HDAC inhibitors are considered to be useful not only as tools for probing the biology of HDAC isozymes but as drugs with low toxicity. Interestingly, it has recently been reported that many non-hydroxamate HDAC inhibitors are inactive against HDAC6 [32, 54-57], indicating the significance of the selectivity of non-hydroxamates. Indeed, compound **9**, one of the

nonhydroxamates presented in this review, was recently reported to show selectivity, whereas SAHA, a representative hydroxamate, did not discriminate well among the HDAC isozymes [39]. Further study on non-hydroxamate HDAC inhibitors will offer a basis on which to better design isozyme-selective inhibitors and to surmount the problems associated with hydroxamates.

## REFERENCES

- [1] White, C. L.; Suto, R. K.; Luger, K. *EMBO J.* **2001**, *20*, 5207.
- [2] Luger, K. *Curr. Opin. Genet. Dev.* **2003**, *13*, 127.
- [3] Berger, S. L. *Curr. Opin. Genet. Dev.* **2002**, *12*, 142.
- [4] Strahl, B. D.; Allis, C. D. *Nature* **2000**, *403*, 41.
- [5] Izuka, M.; Smith, M. M. *Curr. Opin. Genet. Dev.* **2003**, *13*, 154.
- [6] Hassig, C. A.; Schreiber, S. L. *Curr. Opin. Chem. Biol.* **1997**, *1*, 300.
- [7] Kouzarides, T. *Curr. Opin. Genet. Dev.* **1999**, *9*, 40.
- [8] Grozinger, C. M.; Schreiber, S. L. *Chem. Biol.* **2002**, *9*, 3.
- [9] Taunton, J.; Hassig, C. A.; Schreiber, S. L. *Science* **1996**, *272*, 408.
- [10] Sambucetti, L. C.; Fischer, D. D.; Zabudoff, S.; Kwon, P. O.; Chamberlin, H.; Trogani, N.; Xu, H.; Cohen, D. *J. Biol. Chem.* **1999**, *274*, 34940.
- [11] Klisovic, D. D.; Katz, S. E.; Efron, D.; Klisovic, M. I.; Wickham, J.; Parthun, M. R.; Guimond, M.; Marcucci, G. *Invest. Ophthalm. Vis. Sci.* **2003**, *44*, 2390.
- [12] Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 5705.
- [13] Jung, M. *Curr. Med. Chem.* **2001**, *8*, 1505.
- [14] Arts, J.; de Schepper, S.; Van Emelen, K. *Curr. Med. Chem.* **2003**, *10*, 2342.
- [15] Yoshida, M.; Matsuyama, A.; Komatsu, Y.; Nishino, N. *Curr. Med. Chem.* **2003**, *10*, 2351.
- [16] Miller, T. A.; Witter, D. J.; Belvedere, S. *J. Med. Chem.* **2003**, *46*, 5097.
- [17] Monneret, C. *Eur. J. Med. Chem.* **2005**, *40*, 1.
- [18] Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. *Med. Res. Rev.* **2005**, *25*, 261.
- [19] Yoshida, M.; Horinouchi, S.; Beppu, T. *BioEssays* **1995**, *17*, 423.
- [20] Vanhaecke, T.; Papeleu, P.; Elaut, G.; Rogiers, V. *Curr. Med. Chem.* **2004**, *11*, 1629.
- [21] Mai, A.; Massa, S.; Ragno, R.; Cerbara, I.; Jesacher, F.; Loidl, P.; Brosch, G. *J. Med. Chem.* **2003**, *46*, 512.
- [22] Mulder, G. J.; Meerman, J. H. *Environ. Health Perspect.* **1983**, *49*, 27.
- [23] Vassiliou, S.; Mucha, A.; Cuniasso, P.; Georgiadis, D.; Lucet-Levannier, K.; Beau, F.; Kannan, R.; Murphy, G.; Knaeuper, V.; Rio, M. C.; Basset, P.; Yiotakis, A.; Dive, V. *J. Med. Chem.* **1999**, *42*, 2610.
- [24] Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. *Chem. Rev.* **1999**, *99*, 2735.
- [25] Chen, J. S.; Faller, D. V. *Curr. Cancer Drug Targets* **2003**, *3*, 219.
- [26] Gottlicher, M.; Minucci, S.; Zhu, P.; Kramer, O. H.; Schimpf, A.; Giavara, S.; Sleeman, J. P.; Lo Coco, F.; Nervi, C.; Pelicci, P. G.; Heinzel, T. *EMBO J.* **2001**, *20*, 6969.
- [27] Phiel, C. J.; Zhang, F.; Huang, E. Y.; Guenther, M. G.; Lazar, M. A.; Klein, P. S. *J. Biol. Chem.* **2001**, *276*, 36734.
- [28] Lea, M. A.; Sura, M.; desBordes, C. *Cancer Chemo. Pharm.* **2004**, *54*, 57.
- [29] Warrell, R. P.; He, L.; Richon, V.; Calleja, E.; Pandolfi, P. P.; *J. Natl. Cancer Inst.* **1998**, *90*, 1621.
- [30] McLaughlin, F.; La Thangue, N. B. *Biochem. Pharmacol.* **2004**, *68*, 1139.
- [31] Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O. *J. Med. Chem.* **1999**, *42*, 3001.
- [32] Wong, J. C.; Hong, R.; Schreiber, S. L. *J. Am. Chem. Soc.* **2003**, *125*, 5586.
- [33] Vaisburg, A.; Bernstein, N.; Frechette, S.; Allan, M.; Abou-Khalil, E.; Leit, S.; Moradei, O.; Bouchain, G.; Wang, J.; Woo, S. H.; Fournel, M.; Yan, P. T.; Trachy-Bourget, M. C.; Kalita, A.; Beaulieu, C.; Li, Z.; MacLeod, A. R.; Besterman, J. M.; Delorme, D. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 283.
- [34] Bouchain, G.; Delorme, D. *Curr. Med. Chem.* **2003**, *10*, 2359.

- [35] Suzuki, T.; Nagano, Y.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 4321.
- [36] Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3313.
- [37] Suzuki, T.; Matsuura, A.; Kouketsu, A.; Nakagawa, H.; Miyata, N. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 331.
- [38] Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. *J. Med. Chem.* **2005**, *48*, 1019.
- [39] Suzuki, T.; Matsuura, A.; Kouketsu, A.; Hisakawa, S.; Nakagawa, H.; Miyata, N. *Bioorg. Med. Chem.* **2005**, *13*, 4332.
- [40] Wu, T. Y. H.; Hassig, C.; Wu, Y.; Ding, S.; Schultz, P. G. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 449.
- [41] Frey, R. R.; Wada, C. K.; Garland, R. B.; Curtin, M. L.; Michaelides, M. R.; Li, J.; Pease, L. J.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Murphy, S. S.; Davidsen, S. K. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 3443.
- [42] Wada, C. K.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Garland, R. B.; Holms, J. H.; Li, J.; Pease, L. J.; Guo, J.; Glaser, K. B.; Marcotte, P. A.; Richardson, P. L.; Murphy, S. S.; Bouska, J. J.; Tapang, P.; Magoc, T. J.; Albert, D. H.; Davidsen, S. K.; Michaelides, M. R. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3331.
- [43] Vasudevan, A.; Ji, Z.; Frey, R. R.; Wada, C. K.; Steinman, D.; Heyman, H. R.; Guo, Y.; Curtin, M. L.; Guo, J.; Li, J.; Pease, L.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Davidsen, S. K.; Michaelides, M. R. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3909.
- [44] Curtin, M.; Glaser, K. *Curr. Med. Chem.* **2003**, *10*, 2373.
- [45] Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. *Nature* **1999**, *401*, 188.
- [46] Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B.-C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. *Structure* **2004**, *12*, 1325.
- [47] Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; Francesco, R. D.; Gallinari, P.; Steinkühler, C.; Marco, S. D. *Proc. Natl. Acad. Sci. U.S.A.*, **2004**, *101*, 15064.
- [48] Christianson, D. W.; Lipscomb, W. N. *Acc. Chem. Res.* **1989**, *22*, 62.
- [49] Kapstin, G. V.; Fejer, G.; Gronlund, J. L.; McCafferty, D. G.; Seto, E.; Eitzkorn, F. A. *Org. Lett.* **2003**, *5*, 3053.
- [50] Moree, W. J.; van der Marel, G. A.; Liskamp, R. M. J. *Tetrahedron Lett.* **1991**, *32*, 409.
- [51] Christianson, D. W.; Lipscomb, W. N. *J. Am. Chem. Soc.* **1986**, *108*, 4998.
- [52] Gagnard, V.; Leydet, A.; Morere, A.; Montero, J. -L.; Lefebvre, I.; Gosselin, G.; Pannecouque, C.; De Clercq, E. *Bioorg. Med. Chem.* **2004**, *12*, 1393.
- [53] Barber, I.; Rayner, B.; Imbach, J.-L. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 563.
- [54] Matsuyama, A.; Yoshimatsu, Y.; Shimazu, T.; Sumida, Y.; Osada, H.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Horinouchi, S.; Yoshida, M. *EMBO J.* **2002**, *21*, 6820.
- [55] Koeller, K. M.; Haggarty, S. J.; Perkins, B. D.; Leykin, I.; Wong, J. C.; Kao, M. J.; Schreiber, S. L. *Chem. Biol.* **2003**, *10*, 397.
- [56] Glaser, K. B.; Li, J.; Pease, L. J.; Staver, M. J.; Marcotte, P. A.; Guo, J.; Frey, R. R.; Garland, R. B.; Heyman, H. R.; Wada, C. K.; Vasudevan, A.; Michaelides, M. R.; Davidsen, S. K.; Curtin, M. L. *Biochem. Biophys. Res. Commun.*, **2004**, *325*, 683.
- [57] Suzuki, T.; Miyata, N. *Curr. Med. Chem.* **2005**, *12*, 2867.

Copyright of *Mini Reviews in Medicinal Chemistry* is the property of Bentham Science Publishers Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.

Copyright of *Mini Reviews in Medicinal Chemistry* is the property of Bentham Science Publishers Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.